Last reviewed · How we verify
NCT06907004
Developing a Exercise Program for Patients Undergoing Hematopoietic Stem Cell Transplantation
trial in Hematopoietic Stem Cell Transplantation in 24 participants. Completed in 13 October 2023.
13 October 2023
Quick facts
| Lead sponsor | Chimei Medical Center |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 24 |
| Start date | 14 February 2023 |
| Primary completion | 13 October 2023 |
| Estimated completion | 13 October 2023 |
| Sites | 1 location across Taiwan |
Conditions studied
- Hematopoietic Stem Cell Transplantation — all drugs for Hematopoietic Stem Cell Transplantation →
Sponsor
Chimei Medical Center
Who can join
20 and older, any sex, with Hematopoietic Stem Cell Transplantation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Background: Hematopoietic stem cell transplantation (HSCT) is a highly aggressive treatment, which is associated with numerous treatment-related side effects, such as fatigue and decreased functional activity. While recent studies have shown that physical exercise for patients undergoing HSCT is safe and feasible, and has a positive effect on the quality of life, fatigue, and lower limb muscle strength. However, there is no consensus regarding the intensity, type and frequency of exercise program, and few studies mention the patients' experience of exercise barriers and facilitators during HSCT. Therefore, the clinical implementation of exercise program is quite difficult. Purpose: The purpose of this study is to develop a feasible exercise program for hospitalized patients undergoing hematopoietic stem cell transplantation. Methods: Action Research is used to collect quantitative and qualitative data. Through the rolling revision of the exercise program during HSCT, finally develop a feasible exercise program. Expected results: Developing a feasible exercise program for hospitalized patients undergoing hematopoietic stem cell transplantation.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06907004
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hematopoietic Stem Cell Transplantation
Currently open trials in the same condition.
- NCT07400328 — Amimestrocel Injection for Preventing Severe Oral Mucositis in HSCT Patients · Phase 2 · recruiting
- NCT07349498 — Cardiovascular Outcomes and Risk Evaluation Among Recipients of Hematopoietic Stem Cell Transplantation · recruiting
- NCT07442513 — Comparison of Etamsylate Versus Placebo to Prevent Bleeding in HSCT · Phase 3 · recruiting
- NCT06904053 — Metagenomics Next-generation Sequencing Approach to Detect Microbial DNA/RNA Overtime in Individuals Undergoing Hematopo · recruiting
- NCT06708507 — Tissue-resident Immune Cell Subsets in aGVHD · recruiting
Other Chimei Medical Center trials
Trials by the same sponsor.
- NCT06666361 — Middle-aged and Older Adults with Hypertension in Rural Communities · NA · recruiting
- NCT06447441 — Clinical Outcomes Of Mega-dosage Supplementations Of Cholecalciferol In Critically Ill Patients With Sepsis · NA · not yet recruiting
- NCT05493774 — Preliminary Exploration of Applying Multi-person Simulation Training to Improve Nurse-led Burn and Scald Nursing Care · NA · completed
- NCT06429020 — Sonography for COVID-19 Vaccines Related Reactive Lymphadenopathy · completed
- NCT05993741 — Using AR Dental Care Training on Periodontal Status, Blood Sugar Control and QoL in Patients With Type 2 Diabetes · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06907004 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chimei Medical Center
- Last refreshed: 2 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06907004.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing